Search

Your search keyword '"Kang Su Cho"' showing total 10 results
Start Over Author "Kang Su Cho" Journal urologia internationalis
10 results on '"Kang Su Cho"'

1. Efficacy of Adjuvant Gemcitabine-Cisplatin Chemotherapy: A Comparative Study between Locally Advanced Transitional Cell Carcinoma of the Bladder and Upper Urinary Tract

Author

Byung Ha Chung, Won Jae Yang, Chun Il Kim, Seung Hwan Doo, Kang Su Cho, Sung Joon Hong, Yun Seob Song, Se Joong Kim, Jin Seon Cho, and Ki Hak Song

Subjects
Male, Oncology, Time Factors, medicine.medical_treatment, Kaplan-Meier Estimate, urologic and male genital diseases, Deoxycytidine, Risk Factors, Antineoplastic Combined Chemotherapy Protocols, Upper urinary tract, Aged, 80 and over, Middle Aged, female genital diseases and pregnancy complications, Survival Rate, Treatment Outcome, medicine.anatomical_structure, Transitional cell carcinoma, Chemotherapy, Adjuvant, Female, Renal pelvis, Adjuvant, medicine.drug, Adult, Urologic Neoplasms, medicine.medical_specialty, Urology, Risk Assessment, Disease-Free Survival, Ureter, Internal medicine, Republic of Korea, medicine, Humans, Neoplasm Invasiveness, Aged, Neoplasm Staging, Retrospective Studies, Cisplatin, Carcinoma, Transitional Cell, Chemotherapy, Chi-Square Distribution, business.industry, medicine.disease, Gemcitabine, Urinary Bladder Neoplasms, Neoplasm Recurrence, Local, business
Abstract

Objective: To evaluate the comparative efficacy of adjuvant gemcitabine and cisplatin (GC) chemotherapy between patients with locally advanced transitional cell carcinoma (TCC) of the bladder and upper urinary tract. Patients and Methods: From 2001 to 2005, we retrospectively selected a total of 64 patients with locally advanced TCC of the bladder and upper urinary tract who received at least 3 cycles of adjuvant GC chemotherapy. We compared disease-free and overall survival between the 2 groups. Results: The recurrence rate was 30.3% in TCC of the bladder and 25.8% of the upper urinary tract (p = 0.633). Statistical analysis revealed that there was no significant difference in the disease-free or overall survival rate between TCC of the bladder and upper urinary tract treated with adjuvant GC chemotherapy. Conclusion: Under the circumstances of limited data about TCC of the upper urinary tract, this study may suggest that adjuvant GC chemotherapy in locally advanced TCC of the upper urinary tract is as effective as those of bladder.

Published
2010

2. The Prognostic Significance of Pathologic Stage T0 on Organ-Confined Bladder Transitional Cell Carcinoma following Radical Cystectomy

Author

Sung Joon Hong, Joo Wan Seo, Kang Su Cho, Sung Yul Park, Seung Choul Yang, Young Deuk Choi, and Nam Hoon Cho

Subjects
Adult, Male, medicine.medical_specialty, Urology, medicine.medical_treatment, Treatment outcome, Cystectomy, Medical Oncology, Recurrence, medicine, Carcinoma, Humans, Stage (cooking), Aged, Retrospective Studies, Aged, 80 and over, Pathologic stage, Carcinoma, Transitional Cell, Bladder cancer, business.industry, Middle Aged, Prognosis, medicine.disease, Bladder Transitional Cell Carcinoma, Treatment Outcome, Transitional cell carcinoma, Urinary Bladder Neoplasms, Female, business
Abstract

Introduction: We evaluated the prognostic significance of pT0 stage on organ-confined transitional cell carcinoma of the bladder following radical cystectomy. Patients and Methods: We retrospectively reviewed the medical records of consecutive patients who underwent radical cystectomy for organ-confined transitional cell carcinoma of the bladder between 1986 and 2004. Patients who were treated with neoadjuvant or adjuvant therapy were excluded. A total of 197 patients were enrolled in this study. We investigated the impact of pathologic T stage on disease-specific survival. Results: Overall disease-specific survival rate was 84.1% after 5 years. Five-year disease-specific survival rates according to pathologic stage were 88.7% in pT0, 92.2% in pTis-1 and 65.4% in pT2 disease. Overall disease-specific survival rate with pTis-1 or pT0 tumors was significantly higher than with pT2 tumors (p = 0.001, pT2 vs. pT0; p < 0.001, pT2 vs. pTis-1), but there was no difference in disease-specific survival between pTis-1 and pT0 tumors (p > 0.05). In the muscle-invasive tumor group, pT0 tumors had a more favorable prognosis than pT2 tumors (p = 0.042), but there was no difference in prognosis between pT0 and pTis-1 tumors. Conclusions: Pathologic stage T0 cystectomy can be considered a curative therapy in most cases, including pT0cT2 tumors, but there is a substantial risk of tumor recurrence.

Published
2008

3. Contents Vol. 81, 2008

Author

Claudio Panzironi, Faruk Gonenc, Daimantas Milonas, Stephen Wyler, Yasuhide Miyoshi, Klaus Kleinschmidt, C. Leonardo, C. Spiliopoulou, C. Van Audenhove, P.M. Braun, Bruno Guastella, Jun Ju, Yoshinobu Kubota, Soroush Rais-Bahrami, Pier-Luigi Degiorgis, K. Haustermans, Consolato Sergi, Wafaa Jamal, A. Alevizou, Hannes Steiner, Kazuhide Makiyama, Claudia Braun, Seung Choul Yang, F. Sofras, Giuseppe Mario Ludovico, Young Deuk Choi, A. Mariolis, K. De Ridder, Richard E. Hautmann, Luigi Cormio, Yi Rong Chen, Michael Mitterberger, Yusuf Ali, BaoGuang Shi, Nam Hoon Cho, Georg Bartsch, M. Soli, S. Junius, Sung Joon Hong, Joo Wan Seo, Mark Schrader, R. Sacco, Josef Oswald, A. Kumar, Wolf H. Weiske, Berkan Resorlu, Ahmed Magheli, Yuan Li, Amit Khandkar, A. Srivastava, Vincent O. Rotimi, J.R. Scheepe, Christian Radmayr, Viktoras Saferis, Elijah O. Kehinde, Takayuki Murakami, Ahmet Yazicioglu, Mesut Gürdal, A. Alevizos, R. Papalia, Apurva Chaudhary, Kadir Türkölmez, Carsten Kempkensteffen, Pritesh Srimali, Bjoern G. Volkmer, Sümer Baltaci, A. Loreto, Takeshi Watanabe, Yaşar Bedük, M. Gallucci, K. Bovis, Muzaffer Eroglu, N. Gupta, K.P. Jünemann, K. Stamatiou, Ege Can Serefoglu, Ikuo Miyagawa, Önder Kayıgil, Rainer Kuefer, Çağatay Göğüş, S. Isebaert, Kang Su Cho, Fathima Khodakhast, Roberto Ponchietti, Sumiyo Toji, Sung Yul Park, R. Coppola, Nesrin Turhan, F.S. Van Rey, Noboru Nakaigawa, P. Alken, Dong Soo Park, D. Desai, Ahmet Metin, S. Guaglianone, A. Athanasopoulos, H. Van Poppel, J.P.F.A. Heesakkers, Christian Gozzi, Mindaugas Jievaltas, Yogesh Bhandari, Jeong Yun Shim, Jürgen Zumbé, Bruno Giammusso, Mert Altinel, Emre Arpali, S. Joniau, Mohammed Seshah, Masahiro Yao, Nicolai Leonhartsberger, Giovanni M. Colpi, J. Simon, E.J. McGuire, Daniel Porres, Stefan Hinz, G. Simone, Ali Fuat Atmaca, Francesco Montorsi, V. Srinivas, Thomas Akkad, and Cemil Yagci

Subjects
Traditional medicine, business.industry, Urology, Medicine, business
Published
2008

4. Subject Index Vol. 81, 2008

Author

C. Van Audenhove, P.M. Braun, Jun Ju, Pier-Luigi Degiorgis, K. Haustermans, Mohammed Seshah, Kazuhide Makiyama, Masahiro Yao, Nicolai Leonhartsberger, Giovanni M. Colpi, J. Simon, E.J. McGuire, Viktoras Saferis, Elijah O. Kehinde, N. Gupta, Ali Fuat Atmaca, Takayuki Murakami, Yoshinobu Kubota, F. Sofras, Amit Khandkar, Hannes Steiner, Joo Wan Seo, Sung Joon Hong, K. De Ridder, A. Srivastava, J.P.F.A. Heesakkers, Claudio Panzironi, A. Alevizou, Faruk Gonenc, Christian Gozzi, Dong Soo Park, V. Srinivas, Ahmet Metin, Yuan Li, Yi Rong Chen, S. Isebaert, Thomas Akkad, Mesut Gürdal, Luigi Cormio, D. Desai, Nesrin Turhan, Josef Oswald, A. Kumar, Yusuf Ali, BaoGuang Shi, S. Guaglianone, Wolf H. Weiske, Stephen Wyler, Daimantas Milonas, Yasuhide Miyoshi, J.R. Scheepe, H. Van Poppel, Cemil Yagci, S. Junius, Mindaugas Jievaltas, A. Mariolis, Wafaa Jamal, Nam Hoon Cho, A. Alevizos, Önder Kayıgil, A. Athanasopoulos, Noboru Nakaigawa, C. Spiliopoulou, Bruno Guastella, Sümer Baltaci, A. Loreto, Bjoern G. Volkmer, Takeshi Watanabe, Ahmed Magheli, Roberto Ponchietti, Soroush Rais-Bahrami, Yogesh Bhandari, Michael Mitterberger, Sumiyo Toji, Rainer Kuefer, Jürgen Zumbé, Kang Su Cho, Francesco Montorsi, Giuseppe Mario Ludovico, M. Soli, Richard E. Hautmann, Sung Yul Park, Daniel Porres, Çağatay Göğüş, Stefan Hinz, Fathima Khodakhast, K. Bovis, R. Sacco, Vincent O. Rotimi, Jeong Yun Shim, M. Gallucci, G. Simone, Ahmet Yazicioglu, R. Coppola, S. Joniau, Bruno Giammusso, R. Papalia, Apurva Chaudhary, Kadir Türkölmez, F.S. Van Rey, Klaus Kleinschmidt, Mert Altinel, P. Alken, C. Leonardo, Muzaffer Eroglu, K.P. Jünemann, Emre Arpali, Mark Schrader, Georg Bartsch, Yaşar Bedük, Claudia Braun, Seung Choul Yang, Young Deuk Choi, K. Stamatiou, Berkan Resorlu, Christian Radmayr, Carsten Kempkensteffen, Pritesh Srimali, Ege Can Serefoglu, Ikuo Miyagawa, and Consolato Sergi

Subjects
medicine.medical_specialty, Index (economics), business.industry, Urology, General surgery, medicine, Subject (documents), business
Published
2008

5. p53 expression as a prognostic factor in upper urinary tract urothelial carcinoma: a systematic review and meta-analysis

Author

Joo Yong Lee, Kang Su Cho, Young Deuk Choi, Richilda Red Diaz, and Hong Yong Choi

Subjects
Oncology, Male, medicine.medical_specialty, Urologic Neoplasms, Urology, Sex Factors, Predictive Value of Tests, Risk Factors, Internal medicine, medicine, Biomarkers, Tumor, Odds Ratio, Humans, Ureteral neoplasm, P53 expression, Upper urinary tract, Neoplasm Staging, Chi-Square Distribution, business.industry, Carcinoma, Odds ratio, medicine.disease, Up-Regulation, Transitional cell carcinoma, Meta-analysis, Predictive value of tests, Female, Neoplasm Grading, Tumor Suppressor Protein p53, Urothelium, business, Chi-squared distribution
Abstract

Objective: To conduct a meta-analysis examining p53 expression as a potential risk factor in upper urinary tract urothelial carcinoma (UUT-UC) and to systematically review the available data. Methods: A comprehensive literature review was performed from January 1991 to August 2012, using search engines such as PubMed, EMBASE, Cochrane Library and KoreaMed. All retrieved references were manually reviewed, and two authors independently extracted the data. The quality of case-control and cohort studies was assessed using the Scottish Intercollegiate Guidelines Network (SIGN) checklists. Heterogeneity among studies was examined using the Q statistics and Higgins' I2 statistic. Results: Of 302 abstracts of original research studies, nine case-control trials fit our criteria for inclusion in the analysis. Of the nine articles included, four scored ‘low' and five scored ‘modest' in the quality assessment performed according to the SIGN checklists. Analysis of the correlation between different factors and p53 expression in UUT-UC showed that pathologic stage (≥pT3 or Conclusion: The results of our meta-analysis suggest that p53 expression in UUT-UC was correlated with advanced pathologic stage, high histologic grade and female gender.

Published
2013

6. The risk factor for urethral recurrence after radical cystectomy in patients with transitional cell carcinoma of the bladder

Author

Young Hoon Lee, Nam Hoon Cho, Kang Su Cho, Joo Wan Seo, Sung Jin Park, Sung Joon Hong, Seung Choul Yang, and Young Deuk Choi

Subjects
Adult, Male, medicine.medical_specialty, Time Factors, Urology, medicine.medical_treatment, Kaplan-Meier Estimate, Urinary Diversion, Cystectomy, Risk Assessment, Disease-Free Survival, Urethra, Risk Factors, Carcinoma, Medicine, Humans, Neoplasm Invasiveness, Risk factor, Aged, Neoplasm Staging, Proportional Hazards Models, Retrospective Studies, Aged, 80 and over, Carcinoma, Transitional Cell, Urethral Neoplasms, Bladder cancer, business.industry, Incidence (epidemiology), Incidence, Patient Selection, Urinary diversion, Prostate, Retrospective cohort study, Middle Aged, medicine.disease, Transitional cell carcinoma, Treatment Outcome, Urinary Bladder Neoplasms, Neoplasm Recurrence, Local, business, human activities
Abstract

Purpose: We evaluated the incidence and risk factors for urethral recurrence following radical cystectomy and urinary diversion in transitional cell carcinoma. Patients and Methods: A retrospective review was performed of the 412 consecutive patients who underwent radical cystectomy and urinary diversion for transitional cell carcinoma of the bladder between 1986 and 2004. A total of 294 patients were enrolled in this study. We investigated the impact of various clinical and pathological features on urethral recurrence by univariate and multivariate analysis. Results: Urethral recurrence developed in 13 patients (4.4%) and the 5-year urethral recurrence-free probability was 94.9%. On univariate analysis, positive urethral margin, prostatic stromal invasion, and prostatic urethral involvement had a significant influence on urethral recurrence (p < 0.05). The other clinical and pathological features were not significantly associated with urethral recurrence (p > 0.05). A multivariate Cox proportional hazard model revealed that a positive urethral margin (hazards ratio (HR) = 18.33, p < 0.001), prostatic urethral involvement (HR = 7.95, p < 0.001), and prostatic stromal invasion (HR = 5.80, p = 0.018) were independent risk factors for urethral recurrence. Conclusion: A positive urethral margin is considered an absolute indication for prophylactic urethrectomy. In addition, more careful patient selection is necessary for orthotopic urinary diversion in patients with prostatic urethral involvement and prostatic stromal invasion.

Published
2007

7. Acknowledgement to the Reviewers

Author

Viktoras Saferis, Elijah O. Kehinde, Francesco Montorsi, Takayuki Murakami, Amit Khandkar, M. Gallucci, A. Srivastava, Daniel Porres, Muzaffer Eroglu, Stefan Hinz, Nesrin Turhan, Giuseppe Ludovico, C. Van Audenhove, P.M. Braun, G. Simone, Georg Bartsch, Luigi Cormio, Wolf H. Weiske, J.P.F.A. Heesakkers, Jun Ju, Yoshinobu Kubota, Christian Gozzi, Önder Kayıgil, Dong Soo Park, Takeshi Watanabe, Çağatay Göğüş, J.R. Scheepe, Berkan Resorlu, D. Desai, Nam Hoon Cho, Christian Radmayr, C. Leonardo, Noboru Nakaigawa, K. Haustermans, A. Alevizos, Ali Fuat Atmaca, K. Bovis, S. Junius, Mindaugas Jievaltas, Daimantas Milonas, Claudia Braun, Ahmet Metin, Seung Choul Yang, Bruno Giammusso, Mohammed Seshah, Mert Altinel, Young Deuk Choi, R. Coppola, Yi Rong Chen, Ahmed Magheli, Joo Wan Seo, Roberto Ponchietti, F.S. Van Rey, Emre Arpali, Mark Schrader, K. De Ridder, S. Guaglianone, Masahiro Yao, H. Van Poppel, Nicolai Leonhartsberger, Giovanni M. Colpi, E.J. McGuire, V. Srinivas, R. Papalia, P. Alken, A. Athanasopoulos, Yusuf Ali, BaoGuang Shi, Thomas Akkad, Kang Su Cho, Yogesh Bhandari, Wafaa Jamal, Carsten Kempkensteffen, Claudio Panzironi, Faruk Gonenc, Pier-Luigi Degiorgis, Cemil Yagci, Fathima Khodakhast, Kazuhide Makiyama, Jeong Yun Shim, S. Joniau, Pritesh Srimali, Yuan Li, Sumiyo Toji, Klaus Kleinschmidt, F. Sofras, Mesut Gürdal, Sung Yul Park, Rainer Kuefer, Yasuhide Miyoshi, Yaşar Bedük, Ege Can Serefoglu, Ikuo Miyagawa, Soroush Rais-Bahrami, N. Gupta, Hannes Steiner, Jürgen Zumbé, Richard E. Hautmann, S. Isebaert, Consolato Sergi, C. Spiliopoulou, Bruno Guastella, Bjoern G. Volkmer, K. Stamatiou, Josef Oswald, A. Kumar, Sümer Baltaci, A. Loreto, Michael Mitterberger, M. Soli, R. Sacco, Stephen Wyler, K.P. Jünemann, Sung Joon Hong, Vincent O. Rotimi, Ahmet Yazicioglu, Apurva Chaudhary, Kadir Türkölmez, A. Mariolis, A. Alevizou, and Joerg Simon

Subjects
Medical education, business.industry, Urology, Acknowledgement, Medicine, business
Published
2008

8. Efficacy of Adjuvant Gemcitabine-Cisplatin Chemotherapy: A Comparative Study between Locally Advanced Transitional Cell Carcinoma of the Bladder and Upper Urinary Tract.

Author

Yun Seob Song, Jin Seon Cho, Kang Su Cho, Seung Hwan Doo, Byung Ha Chung, Se Joong Kim, Won Jae Yang, Ki Hak Song, Chun Il Kim, and Sung Joon Hong

Subjects
CISPLATIN, CANCER cells, BLADDER cancer, URINARY tract infections, DRUG therapy, IMMUNOLOGICAL adjuvants
Abstract

Objective: To evaluate the comparative efficacy of adjuvant gemcitabine and cisplatin (GC) chemotherapy between patients with locally advanced transitional cell carcinoma (TCC) of the bladder and upper urinary tract. Patients and Methods: From 2001 to 2005, we retrospectively selected a total of 64 patients with locally advanced TCC of the bladder and upper urinary tract who received at least 3 cycles of adjuvant GC chemotherapy. We compared disease-free and overall survival between the 2 groups. Results: The recurrence rate was 30.3% in TCC of the bladder and 25.8% of the upper urinary tract (p = 0.633). Statistical analysis revealed that there was no significant difference in the disease-free or overall survival rate between TCC of the bladder and upper urinary tract treated with adjuvant GC chemotherapy. Conclusion: Under the circumstances of limited data about TCC of the upper urinary tract, this study may suggest that adjuvant GC chemotherapy in locally advanced TCC of the upper urinary tract is as effective as those of bladder. Copyright © 2010 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

9. The Risk Factor for Urethral Recurrence after Radical Cystectomy in Patients with Transitional Cell Carcinoma of the Bladder.

Author

Kang Su Cho, Joo Wan Seo, Sung Jin Park, Young Hoon Lee, Young Deuk Choi, Nam Hoon Cho, Seung Choul Yang, and Sung Joon Hong

Subjects
*BLADDER cancer, *CANCER patients, *PATHOLOGY, *CANCER treatment, *URINARY diversion, *URINARY organs
Abstract

Purpose: We evaluated the incidence and risk factors for urethral recurrence following radical cystectomy and urinary diversion in transitional cell carcinoma. Patients and Methods: A retrospective review was performed of the 412 consecutive patients who underwent radical cystectomy and urinary diversion for transitional cell carcinoma of the bladder between 1986 and 2004. A total of 294 patients were enrolled in this study. We investigated the impact of various clinical and pathological features on urethral recurrence by univariate and multivariate analysis. Results: Urethral recurrence developed in 13 patients (4.4%) and the 5-year urethral recurrence-free probability was 94.9%. On univariate analysis, positive urethral margin, prostatic stromal invasion, and prostatic urethral involvement had a significant influence on urethral recurrence (p < 0.05). The other clinical and pathological features were not significantly associated with urethral recurrence (p > 0.05). A multivariate Cox proportional hazard model revealed that a positive urethral margin (hazards ratio (HR) = 18.33, p < 0.001), prostatic urethral involvement (HR = 7.95, p < 0.001), and prostatic stromal invasion (HR = 5.80, p = 0.018) were independent risk factors for urethral recurrence. Conclusion: A positive urethral margin is considered an absolute indication for prophylactic urethrectomy. In addition, more careful patient selection is necessary for orthotopic urinary diversion in patients with prostatic urethral involvement and prostatic stromal invasion. Copyright © 2009 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

10. The Prognostic Significance of Pathologic Stage T0 on Organ-Confined Bladder Transitional Cell Carcinoma following Radical Cystectomy.

Author

Kang Su Cho, Joo Wan Seo, Sung Yul Park, Nam Hoon Cho, Young Deuk Choi, Seung Choul Yang, and Sung Joon Hong

Subjects
*BLADDER cancer, *ADJUVANT treatment of cancer, *TUMORS, *ONCOLOGY, *CYSTS (Pathology)
Abstract

Introduction: We evaluated the prognostic significance of pT0 stage on organ-confined transitional cell carcinoma of the bladder following radical cystectomy. Patients and Methods: We retrospectively reviewed the medical records of consecutive patients who underwent radical cystectomy for organ-confined transitional cell carcinoma of the bladder between 1986 and 2004. Patients who were treated with neoadjuvant or adjuvant therapy were excluded. A total of 197 patients were enrolled in this study. We investigated the impact of pathologic T stage on disease-specific survival. Results: Overall disease-specific survival rate was 84.1% after 5 years. Five-year disease-specific survival rates according to pathologic stage were 88.7% in pT0, 92.2% in pTis-1 and 65.4% in pT2 disease. Overall disease-specific survival rate with pTis-1 or pT0 tumors was significantly higher than with pT2 tumors (p = 0.001, pT2 vs. pT0; p < 0.001, pT2 vs. pTis-1), but there was no difference in disease-specific survival between pTis-1 and pT0 tumors (p > 0.05). In the muscle-invasive tumor group, pT0 tumors had a more favorable prognosis than pT2 tumors (p = 0.042), but there was no difference in prognosis between pT0 and pTis-1 tumors. Conclusions: Pathologic stage T0 cystectomy can be considered a curative therapy in most cases, including pT0cT2 tumors, but there is a substantial risk of tumor recurrence. Copyright © 2008 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results